...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

CEVEC to launch human CAP-T™ Cell Expression System

| Print |
Thursday, 05 March 2009 08:33 (UTC + 1)


Cevec_logo


CEVEC to launch CAP-T™ Cell System -
Industry’s State of the Art Human Transient Expression Technology


Cologne, Germany, March 5, 2009 / b3c newswire / - CEVEC Pharmaceuticals GmbH, specializing in the development of complex therapeutic proteins using proprietary human cell-based expression systems, introduces novel CAP-T™ transient expression system for fast, serum-free and high yield protein production. CAP-T™ Technology is the logic result of today’s demand towards creating an efficient, integrated platform for transient production of complex biologics.

 

With CAP-T™ customers can proceed from gene to milligram and gram amounts of protein within only two weeks. Fast process times, high yields and authentic human post-translational modifications especially with complex and highly glycosylated proteins are key features and make it an ideal tool for screening, assay development, target validation, drug discovery, early stage pre-clinical drug development, and lead optimization.

 

Dr. Rainer Lichtenberger, CEO of CEVEC, comments: “Starting with transient protein expression using CAP-T™ and moving forward with stable expression using CAP® cells, CEVEC is now able to offer a continuum for rapid and versatile biopharmaceutical drug development from initial research ideas up to GMP-compliant manufacturing of clinical samples and market supplies.”

 

CAP-T™ cells are based on CAP® cells and match all their positive features with regard to comprehensive documentation, safety, non-tumor origin, and growth as suspension culture in serum- and protein-free media optimized for industrial use. CAP-T™ is available under flexible research license arrangements.

 

 

About CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing complex therapeutic proteins with human glycosylation patterns. CEVEC’s novel proprietary human CAP® and CAP-T™ expression systems are ideal for manufacturing complex biopharmaceutical molecules. CEVEC is licensing out its human cell-based expression platform as well as biological product candidates from internal development through partnerships with renowned pharmaceutical and biotech companies.

 


Contact:
CEVEC Pharmaceuticals GmbH
Dr. Rainer Lichtenberger, CEO
Gottfried-Hagen-Str. 62
51105 Köln, Germany
Tel *49 221 46 02 08 10
Fax *49 221 46 02 08 01
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.cevec-pharmaceuticals.com